OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces it has been invited to present its research and commercial developments at..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announced today that it has entered into a scale up and manufacturing agreement..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announced today its results for the six months ended 31 May 2017. This..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it plans for a US launch of LPLDL®,..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care announced today that, further to the European manufacturing and supply agreement..
OptiBiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara caught up with DirectorsTalk for an exclusive interview to discuss the recent share price movement, their deal pipeline, the 39 potential..
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the recent share price movement. Stephen also talks about the potential for 39 RNS’s that could be announced over..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that HLH BioPharma Vertriebs GmbH (“HLH”) have achieved product..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to develop and supply three different..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announced today successful human taste studies in its SweetBiotix® product development programme. The..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it has entered into a three year supply..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes announced today the successful launch of its SlimBiome® and LPLDL® products at the..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it has agreed to grant a non-exclusive license..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it has had an abstract accepted for presentation..
OptiBiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara caught up with DirectorsTalk for an exclusive interview to discuss the listing of SkinBiotherapeutics PLC onto the AIM market, what this..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announced today its audited results for the year ended 30 November 2016. The..
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the listing of SkinBiotheraputics (LON:SBTX). Stephen explains the rationale behind the launch, what this could mean for OptiBiotix investors,..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30 November..
DirectorsTalk caught up with Optibiotix Health Plc (LON:OPTI) CEO Stephen OHara to comment on today’s news that sugar limits for everyday foods such as biscuits, chocolate bars and cereals have..
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that its majority owned subsidiary, SkinBioTherapeutics (formerly SkinBiotix), intends..
